This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial


Culo, Sandi, Mulsant, Benoit H., Rosen, Jules, Mazumdar, Sati, Blakesley, Richard E., Houck, Patricia R., Pollock, Bruce G.


Alzheimer Disease And Associated Disorders, Volume: 24, No.: 4, Pages.: 360-364

Year of Publication



Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and 66 with AD hospitalized for behavioral disturbance were treated under randomized, double-blind conditions with citalopram or risperidone for up to 12 weeks. Neuropsychiatric symptoms were assessed with the nursing home version of the Neuropsychiatric Inventory (NPI) and the Clinical Global Impression of Change (CGIC). Side effects were measured using the UKU Side Effect Rating Scale. A significantly higher proportion of participants with DLB (68%) than with AD (50%) discontinued the study prematurely. Discontinuation rates were comparable in DLB participants treated with citalopram (71%) or risperidone (65%). However, participants with DLB randomized to risperidone experienced a higher overall burden of side effects. Scores on the NPI and the CGIC worsened in DLB participants and improved in those with AD. Most patients with behavioral disturbances or psychosis associated with DLB tolerate citalopram or risperidone poorly and do not seem to benefit from either medication.;

Bibtex Citation

@article{Culo_2010, doi = {10.1097/wad.0b013e3181e6a4d7}, url = {}, year = 2010, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {24}, number = {4}, pages = {360--364}, author = {Sandi Culo and Benoit H. Mulsant and Jules Rosen and Sati Mazumdar and Richard E. Blakesley and Patricia R. Houck and Bruce G. Pollock}, title = {Treating Neuropsychiatric Symptoms in Dementia With Lewy Bodies}, journal = {Alzheimer Disease {&} Associated Disorders} }


adverse, adverse effects, aged, 80 and over, and, antipsychotic agents, citalopram, complications, double-blind method, drug therapy, etiology, events, female, humans, lewy body disease, male, neuropsychological tests, psychiatric status rating scales, psychology, psychotic disorders, risperidone, therapeutic use, treatment outcome

Countries of Study


Types of Dementia


Types of Study

Randomised Controlled Trial

Type of Outcomes

Behaviour, Other


Hospital Inpatient Care

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Antipsychotics and antidepressants